Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2  by Hortobagyi, Gabriel N.
www.neoplasia.com
Volume 17 Number 3 March 2015 pp. 279–288 279Everolimus Plus Exemestane for the
Treatment of Advanced Breast
Cancer: A Review of Subanalyses
from BOLERO-21Gabriel N. Hortobagyi
Department of Breast Medical Oncology, The University of
Texas MD Anderson Cancer Center, Houston, TX, USAAbstract
Hormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resistance to
endocrine therapy results in disease progression in a large proportion of breast cancers. Through the
understanding of the mechanisms of endocrine resistance, identification of implicated pathways and targets
has led to the development of novel agents targeting these pathways. Phosphoinositide 3-kinase/protein kinase B/
mammalian target of rapamycin (PI3K/AKT/mTOR) pathway aberrations are common in breast cancer, with
increased PI3K/AKT/mTOR signaling associated with resistance to endocrine and human epidermal growth factor
receptor 2 (HER2)–targeted therapies. The mTOR inhibitor everolimus, in combination with exemestane, has been
approved for patients with advanced hormone receptor–positive/HER2-negative breast cancer who progress on
prior nonsteroidal aromatase inhibitor therapy based on results reported in the Breast Cancer Trials of Oral
Everolimus-2 (BOLERO-2) study. This review will summarize the overall findings from BOLERO-2 and will consider
available subanalyses by age, Asian origin, visceral or bone metastases, and prior therapy, with the aim of
identifying populations most likely to benefit from everolimus therapy. The review will also summarize safety
findings and their management and the effects of everolimus on quality of life.
Neoplasia (2015) 17, 279–288Abbreviations: AE, adverse event; BSAP, bone-specific alkaline phosphatase; CBR,
clinical benefit rate; CR, complete response; CTX, C-terminal cross-linking telopeptide
of type 1 collagen; HER2, human epidermal growth factor receptor 2; HR, hazard ratio;
NIP, noninfectious pneumonitis; ORR, objective response rate; PI3K/AKT/mTOR,
phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin; PFS,
progression-free survival; P1NP, amino-terminal propeptide of type 1 collagen; PR,
partial response; QoL, quality of life; TDD, time to definitive deterioration
Address all correspondence to: Gabriel N. Hortobagyi, MD, FACP, FASCO,
Department of Breast Medical Oncology, The University of Texas MD Anderson
Cancer Center, PO Box 301429, Houston, TX, USA.
E-mail: ghortoba@mdanderson.org
1Editorial support in the preparation of this manuscript was provided by Tricia Newell
and Matthew Grzywacz (ApotheCom, Yardley, PA). This editorial support was funded
by Novartis Pharmaceuticals Corporation. Conflict of interest statement: During the
past 24 months, G.N.H. has served on advisory boards for Antigen Express, Galena
Biopharma, Novartis Pharmaceuticals, Oncimmune, Peregrine Pharmaceuticals, and
Pfizer, and he has received research grants from Novartis to support a clinical trial. He
has no additional financial disclosures to report.
Received 3 November 2014; Revised 19 January 2015; Accepted 23 January 2015
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by/4.0/).
1476-5586/15
http://dx.doi.org/10.1016/j.neo.2015.01.005Introduction
Breast cancer is the leading cause of cancer death among women
worldwide [1]. In the United States in 2014, more than 232,670
women will be diagnosed with breast cancer and 40,000 are predicted
to die of this disease [2].
Approximately 75% of breast cancers are hormone receptor–positive
[3,4] and are typically managed with endocrine therapies, including
aromatase inhibitors and selective estrogen receptor modulators [5,6].
However, primary or acquired resistance to endocrine therapy results in
disease progression in a large proportion of breast cancers [7,8]. Through
the understanding of the mechanisms of endocrine resistance,
identification of implicated pathways and targets has led to the
development of novel agents targeting these pathways [9–12].
Phosphoinositide 3-kinase/protein kinase B/mammalian target of
rapamycin (PI3K/AKT/mTOR) pathway aberrations are common in
breast cancer [13], with activating mutations in PIK3CA present in
about one quarter of breast cancers [13–15]. PI3K/AKT/mTOR
pathway abnormalities are present in both primary tumors and
metastases [16,17], and increased PI3K/AKT/mTOR signaling is
associated with resistance to endocrine and human epidermal growth
factor receptor 2 (HER2)–targeted therapies and relapse [18–21].
Table 1. Summary of Baseline Patient and Disease Demographics in BOLERO-2 [24,25]
Everolimus Plus
Exemestane
Placebo Plus
Exemestane
Overall n = 485 n = 239
Median age (range), years 62 (34-93) 61 (28-90)
≥65 years, % 40 33
≥70 years, % 25 18
Ethnicity, %
White 74 78
Asian 20 19
Black 3 1
Other 3 2
Visceral disease, % 58 59
Metastatic site, %
Lung 30 33
Liver 33 30
Bone 77 77
Setting of most recent treatment, %
Adjuvant 21 16
Advanced/metastatic disease 79 84
Prior therapy, %
Letrozole/anastrozole as most recent therapy 74 75
Tamoxifen 47 50
Fulvestrant 17 16
Chemotherapy (any setting) 69 65
Chemotherapy (for metastatic disease) 26 26
Radiotherapy 70 69
Number of prior therapies, %
1-2 46 47
≥3 54 53
* Prior therapies include those used in the adjuvant setting or to treat advanced disease.
Adapted with kind permission of Springer Science + Business Media; Advances in therapy,
everolimus plus exemestane in postmenopausal patients with hormone receptor–positive breast
cancer: BOLERO-2 final progression-free survival analysis, 2013:30(10):870–884, Yardley,
D.A., et al. © The Authors 2013.
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tane, has been approved for patients with advanced hormone
receptor–positive/HER2-negative (HER2−) breast cancer who
progress on prior endocrine therapy with either letrozole or
anastrozole [22], based on the results from the Breast Cancer Trials
of Oral Everolimus-2 (BOLERO-2) study [23,24]. This review will
summarize the overall findings from BOLERO-2 and will consider
available subanalyses and safety findings, with the aim of identifying
populations most likely to benefit from everolimus therapy.
Primary Findings from BOLERO-2
The BOLERO-2 study was an international, double-blind, random-
ized, phase III study comparing everolimus plus exemestane to
placebo plus exemestane in postmenopausal women with hormone
receptor–positive/HER2− advanced breast cancer progressing during
or following nonsteroidal aromatase inhibitor therapy with either
letrozole or anastrozole, defined as recurrence during or within 12
months after the end of adjuvant treatment or progression during or
within 1 month after the end of treatment for advanced disease [23].
Patients received open-label exemestane and were randomly assigned
to blinded therapy with either everolimus or placebo, and
randomization was stratified according to the presence of visceral
metastases and sensitivity to prior hormonal therapy [24]. Inclusion
criteria allowed disease recurrence during or within 12 months after
completion of adjuvant endocrine therapy, one prior line of
chemotherapy for advanced breast cancer, and disease progression
within 1 month after treatment for advanced breast cancer [23].
The primary end point of BOLERO-2 was progression-free
survival (PFS) based on local assessment, and secondary end points
included overall survival, objective response rate (ORR), quality of life
(QoL), bone markers, and safety [23,24]. Tumors were evaluated by
Response Evaluation Criteria In Solid Tumors (version 1.0) based on
investigator assessment and supported by an independent radiology
committee (central assessment).
BOLERO-2 included 724 patients (485 in the everolimus plus
exemestane arm; 239 in the placebo plus exemestane arm) [23].
Baseline patient and disease characteristics are summarized in Table 1.
At the final analysis after a median follow-up of 18months, median PFS
based on investigator assessment (local assessment) was 7.8 months in
the everolimus plus exemestane arm and 3.2 months in the placebo plus
exemestane arm [hazard ratio (HR), 0.45; 95% confidence interval
(CI), 0.38-0.54; P b .0001; Table 2] [24]. Consistent results based on
independent central assessment were observed (11.0 vs 4.1 months;
HR, 0.38; 95% CI, 0.31-0.48; P b .0001).
Secondary end points from BOLERO-2 also favored everolimus
plus exemestane therapy. ORR [complete response (CR) or partial
response (PR)] was 12.6% (95% CI, 9.8-15.9) in the everolimus plus
exemestane arm and 1.7% (0.5-4.2) in the placebo plus exemestane
arm (P b .0001; local assessment) [24]. Median duration of overall
response was 10.5 months (95% CI, 8.2-21.9) in the everolimus plus
exemestane arm and 6.9 months (95% CI, 4.2-6.9) in the placebo
plus exemestane arm [31]. Because the proportion of patients with a
tumor response in each treatment arm was low, overall median time
to response could not be determined for the overall population.
Among patients with a CR or PR, the median time to response was
2.8 months (range, 1.2-19.4 months) in the everolimus plus
exemestane arm and 5.0 months (range, 1.3-12.2 months) in the
placebo plus exemestane arm [31]. Clinical benefit rate (CBR; CR +
PR + stable disease for ≥24 weeks) was 51.3% (95% CI, 46.8-55.9)and 26.4% (95% CI, 20.9-32.4) in the everolimus plus exemestane
and placebo plus exemestane arms, respectively (P b .0001; by local
assessment) [24]. Median overall survival was 31.0 months (95% CI,
28.0-34.6) with everolimus plus exemestane and 26.6 months (95%
CI, 22.6-33.1) with placebo plus exemestane (HR, 0.89; 95% CI,
0.73-1.10; stratified log-rank P = .1426) [32]. The authors high-
lighted some potential reasons for the lack of statistical significance in
overall survival [32]. One reason was that there was a lack of power to
detect a realistic overall survival advantage because the chosen sample
size was based on the primary end point of PFS. Additionally,
clinicians may have been able to determine if patients were not
receiving study treatment due to the absence of adverse events (AEs)
associated with mTOR inhibitors (e.g., stomatitis), and this may have
encouraged the initiation of more aggressive treatments (e.g.,
chemotherapy) after progression [32].
The most commonly reported AEs (affecting N30% of patients) in
the everolimus plus exemestane arm included stomatitis (59% and
12% in the everolimus plus exemestane and placebo plus exemestane
arms, respectively), rash (39% and 7%), fatigue (37% and 27%),
diarrhea (34% and 19%), nausea (31% and 29%), and decreased
appetite (31% and 13%) [24]. Half of the patients in the everolimus
plus exemestane arm experienced grade 3/4 AEs, with 27% of
patients in the placebo plus exemestane arm reporting grade 3/4 AEs
[22]. The most common grade 3/4 AEs with everolimus plus
exemestane compared to placebo plus exemestane included stomatitis
(8% and b1%), gamma-glutamyltransferase increase (7% and 7%),
anemia (7% and 1%), hyperglycemia (5% and b1%), fatigue (4%
and 1%), and dyspnea (5% and 1%) [24].
Table 2. Summary of PFS Results for BOLERO-2, Including the Primary Analysis and Subanalyses
Everolimus +
Exemestane, Median
PFS, Months
Placebo +
Exemestane, Median
PFS, Months
HR 95% CI P Value
Overall population [24] 7.8 3.2 0.45 0.38-0.54 b .0001
Elderly [25]
≥65 years 6.8 4.0 0.59 0.43-0.80 –
≥70 years 6.8 1.5 0.45 0.30-0.68 –
b65 years 8.3 2.9 0.38 0.30-0.47 –
Prior therapy
Chemotherapy [26] 6.1 2.7 0.38 0.27-0.53 –
Adjuvant therapy
[26,27]
11.5 4.1 0.39 0.25-0.62 –
Visceral disease [28]
Yes 6.8 2.8 0.47 0.37-0.60 b .05
No 9.9 4.2 0.41 0.31-0.55 b .05
Bone-only metastases
[28]
12.9 5.3 0.33 0.21-0.53 b .05
Ethnicity [29]
Asian 8.5 4.1 0.62 0.41-0.94 –
Non-Asian 7.3 2.8 0.41 0.33-0.50 –
ILC [30] 6.9 4.2 0.59 0.37-0.95 –
CI, confidence interval; HR, hazard ratio; ILC, invasive lobular carcinoma; PFS, progression-free survival.
Note: All analyses are based on investigator (local) assessment at the final analysis at a median follow-up of
18 months.
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Patient numbers in the populations included in the subanalyses are
summarized in Table 1, and median PFS results for the individual
subanalyses are summarized in Table 2. As summarized in the final
PFS analysis of BOLERO-2 after a median follow-up of 18 months,
the effect of everolimus plus exemestane treatment was consistent
across subgroups defined by patient characteristics and prior therapy
(estimated HR of 0.25 and 0.62, respectively), with everolimus plus
exemestane increasing PFS benefits compared with placebo plus
exemestane regardless of baseline disease or prior therapy character-
istics [24]. These findings and other subanalyses are described in more
detail in the following section.
Elderly Patients
The median age for breast cancer diagnosis in North America is
61 years [33,34]; more than 40% of patients with breast cancer are
aged ≥65 years [34] and approximately 10% are aged N80 years [35].
Although breast cancer incidence and deaths in females aged
N65 years is higher than in younger age groups [36], the limited
availability of randomized studies in elderly patients hinders selection
of optimal treatment in this patient population, particularly in those
with comorbidities and susceptibility to AEs [25].
In BOLERO-2, protocol-specified analyses included results for
patients aged ≥65 years (38% of those in the study or 275/724
patients), while analyses for those aged ≥70 years (23% of those in the
study or 164/724 patients) were exploratory [25]. Disease and
pretreatment characteristics were generally comparable between
elderly (≥65 years) and younger (b65 years) age groups. Baseline
performance status of the elderly population was slightly worse than
that of younger patients. In addition, previous use of neoadjuvant/
adjuvant chemotherapy was less common in older patients, and there
were differences in rates of certain comorbidities (such as respiratory
system abnormalities, metabolic and nutritional disorders, and
vascular disorders) between the two populations.
PFS results favored everolimus plus exemestane treatment in the
age-defined subgroups (≥65 years, b65 years, 70 years) [25]. MedianPFS in patients ≥65 years was 6.8 compared with 4.0 months (HR,
0.59; 95% CI, 0.43-0.80) in the everolimus plus exemestane and
placebo plus exemestane arms, respectively. Similarly, median PFS in
patients aged ≥70 years and b65 years in the everolimus plus
exemestane and placebo plus exemestane arms, respectively, was 6.8
and 1.5 months (HR, 0.45; 95% CI, 0.30-0.68) and 8.3 and
2.9 months (HR, 0.38; 95% CI, 0.30-0.47).
CBR in the everolimus plus exemestane arm was greater than in the
placebo plus exemestane arm in all age subgroups, respectively, with CBR
rates of 41% versus 31% in patients aged ≥65 years, 36% versus 23% in
those aged ≥70 years, and 58% versus 24% in those aged b65 years [25].
Similarly, ORR also favored everolimus plus exemestane over placebo
plus exemestane in all age groups, respectively, with ORR rates of 9%
versus 5% in those aged ≥65 years, 9% versus 7% in those aged
≥70 years, and 15% versus 0% in those aged b65 years [25].
Comparable safety profiles among older and younger patients were
observed [25]. There was lower mean duration of everolimus
exposure in older compared with younger patients, but the dose
intensity remained similar among age groups. The incidence of AEs
was similar among patients aged ≥65, ≥70, and b65 years, including
stomatitis (53% vs 49% vs 63%, respectively), pneumonitis (15% vs
14% vs 17%), hyperglycemia (13% vs 12% vs 15%), and
hypercholesterolemia (6% vs 7% vs 13%).
Results from this analysis showed that no dosage adjustment of
initial dosing is required in elderly patients who have no other health
concerns [22]. However, close monitoring is recommended for these
patients, and the everolimus dose should be adjusted if appropriate as
AEs occur.
Prior Therapy
Subpopulations of patients who progressed on anastrozole or
letrozole and who were enrolled in BOLERO-2 included those whose
disease recurred during or after neoadjuvant/adjuvant therapy and
those who had one line of prior chemotherapy for advanced breast
cancer [26]. The effect of prior therapy on outcomes from
BOLERO-2 was assessed as an exploratory analysis [26,27].
Prior Chemotherapy. In BOLERO-2, 26% (186/724) of patients
in the overall population received prior chemotherapy for advanced
breast cancer, with 12% having received greater than or equal to three
therapies before starting study treatment [26]. Of those patients who
received prior chemotherapy, 48% (90/186) were treated with
chemotherapy in the advanced setting and 52% (96/186) were
treated in both the neoadjuvant/adjuvant and advanced disease
settings. The incidence of visceral disease was higher for patients who
had prior chemotherapy for advanced breast cancer compared with
those who did not (67% vs 56%), and disease recurrence less than
6 months after initial diagnosis of advanced or metastatic breast
cancer was noted in 32% of patients who received prior
chemotherapy compared with 17% of patients who had not.
Median PFS increased in the everolimus plus exemestane arm
versus the placebo plus exemestane arm in patients who received prior
chemotherapy for advanced breast cancer (6.1 vs 2.7 months; HR,
0.38; 95% CI, 0.27-0.53) [26]. The most common AEs in patients
who received prior chemotherapy were stomatitis (53% and 18% for
everolimus plus exemestane and placebo plus exemestane, respective-
ly), diarrhea (31% and 8%), rash (36% and 3%), and fatigue (35%
and 25%). The most common grade 3/4 AEs in this subgroup were
stomatitis (9% and 2%), hyperglycemia (6% and 0%), fatigue (4%
and 2%), and pneumonitis (4% and 0%). The AE profile in patients
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common AEs reported in the overall population and the known safety
profile of everolimus.
Prior Adjuvant Therapy
In BOLERO-2, approximately 20% of patients had disease
recurrence during or within 12 months of completing adjuvant
therapy (21% in the everolimus plus exemestane arm and 15% in the
placebo plus exemestane arm), with almost all of these patients having
letrozole or anastrozole as their last therapy before study entry (98%
and 100%, respectively) [26,27]. Overall, 89% of patients in both
arms were randomly assigned to the study b3 months from first
recurrence; 137 patients received first-line everolimus plus exemes-
tane (n = 100) or placebo plus exemestane (n = 37) in the advanced
setting. Of these patients, 74% in the everolimus plus exemestane
arm and 76% in the placebo plus exemestane arm recurred after
adjuvant endocrine therapy plus chemotherapy, and 26% of patients
in the everolimus plus exemestane arm and 24% in the placebo plus
exemestane arm recurred after adjuvant endocrine therapy alone
[26,27].
Everolimus plus exemestane increased median PFS compared with
placebo plus exemestane (11.5 vs 4.1 months; HR, 0.39; 95% CI,
0.25-0.62) in patients who recurred after adjuvant therapy, suggesting
efficacy as first-line everolimus therapy in the advanced setting
[26,27]. Among patients who had undergone prior neoadjuvant/
adjuvant treatment as the last prior therapy, valid data for target lesion
diameters were available for 62 of 100 patients in the everolimus plus
exemestane arm and 23 of 37 patients in the placebo plus exemestane
arm, with decreases from baseline in the sum of the longest target
lesion diameters by local assessment shown for 79% of patients with
prior neoadjuvant/adjuvant therapy in the everolimus plus exemes-
tane arm and 30% in the placebo plus exemestane arm [31].
The most common AEs in patients who recurred during or after
adjuvant therapy were stomatitis (68% and 22% for everolimus plus
exemestane and placebo plus exemestane, respectively), diarrhea
(40% and 22%), rash (37% and 8%), and fatigue (32% and 16%)
[26,27]. The most common grade 3/4 AEs in this subgroup were
hyperglycemia (8% and 3%), stomatitis (4% and 0%), diarrhea (4%
and 0%), and fatigue (3% and 3%). This AE profile is consistent with
the most common AEs reported in the overall population and the
known safety profile of everolimus.
These findings with everolimus in both prior therapy subsets
suggest that, compared with the overall population, everolimus is
effective in patients who received prior chemotherapy for advanced
breast cancer and had high tumor burden. The findings also provide
support for first-line therapy with everolimus in combination with
exemestane for disease recurrence during or after adjuvant nonste-
roidal aromatase inhibitor therapy [26].
Visceral Disease
Many postmenopausal patients with hormone receptor–positive
advanced breast cancer present with visceral metastases [37]. First
metastasis is estimated to occur in the skeletal system in 46% of patients,
in the visceral organs in 41%, and in both systems in 13%; disease remains
in the bone or visceral organs in about 60% of patients and develops into
bone and visceral metastases in greater than 40% of patients [38].
In an exploratory analysis of the BOLERO-2 study, the efficacy
and safety of everolimus plus exemestane were evaluated according to
the presence of visceral disease, which was reported in 56% (406/724)of patients in both treatment arms [28]. Of the patients with visceral
disease, 84% had greater than or equal to two metastatic sites and
50% had greater than or equal to three metastatic sites [28].
Metastatic sites included the lung (in ~45% of patients), liver (50%),
and metastases to both sites (14%).
Among patients with visceral metastases, median PFS was
6.8 months in the everolimus plus exemestane arm compared with
2.8 months in the placebo plus exemestane arm (HR, 0.47; 95% CI,
0.37-0.60; P b .05); among patients without visceral metastases,
median PFS was 9.9 months in the everolimus plus exemestane arm
compared with 4.2 months in the placebo plus exemestane arm (HR,
0.41; 95% CI, 0.31-0.55; P b .05) [28].
Improvements in PFS with everolimus therapy were seen in all
patients irrespective of Eastern Cooperative Oncology Group
(ECOG) performance status, with patients with visceral metastases
and an ECOG performance status of 0 having a median PFS of
6.8 months in the everolimus plus exemestane arm versus 2.8 months
in the placebo plus exemestane arm (HR, 0.54; 95% CI, 0.40-0.73;
P b .05) [28]. In patients with visceral metastases and an ECOG
performance status ≥1, the median PFS with everolimus plus
exemestane was more than three times longer than that of placebo
plus exemestane (6.8 vs 1.5 months, respectively).
CBR was significantly higher among patients treated with
everolimus plus exemestane versus placebo plus exemestane, irrespec-
tive of visceral involvement (no visceral disease at baseline: 60% vs
32%, respectively; visceral disease at baseline: 45% vs 22%) [28].
Patients with visceral disease had a similar CBR with everolimus
therapy independent of ECOG performance status.
Among patients with baseline visceral disease, valid data for target
lesion diameters were available for 224 of 271 patients in the
everolimus plus exemestane arm and 107 of 135 patients in the
placebo plus exemestane arm, with decreases from baseline in the sum
of the longest target lesion diameters by local assessment shown for
69% of patients with baseline visceral disease in the everolimus plus
exemestane arm versus 27% in the placebo plus exemestane arm [31].
The incidence of AEs was generally similar in patients with or
without visceral disease, with no increased risk of any specific AE in
patients with visceral metastases [28]. The most common AEs for
patients receiving everolimus with visceral versus nonvisceral disease
were stomatitis (59% and 59%, respectively), rash (40% and 39%),
fatigue (40% and 36%), decreased appetite (36% and 24%), and
diarrhea (34% and 34%); this AE profile was consistent with the
overall study population.
This subanalysis of BOLERO-2 highlights that everolimus in
combination with exemestane may be a potential alternative to
chemotherapy for patients whose visceral metastases are not
immediately life threatening [28].
Bone Disease
The bone of patients with breast cancer may be adversely affected
by both the disease and some breast cancer therapies [39,40]. The
interaction of breast cancer and bone cells causes intracellular
signaling that promotes the growth and spread of bone metastases,
and breast cancer cells can secrete factors promoting osteolysis,
causing bone destruction and tumor growth [39]. Endocrine
therapies can also increase bone loss, thereby exacerbating bone-
related complications in patients with breast cancer [40].
Because everolimus was used in combination with exemestane,
which is known to increase bone turnover [40], exploratory analyses
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turnover markers at 6 and 12 weeks, were performed in the
BOLERO-2 trial [41]. The presence of bone metastases at baseline
was comparable between treatment arms (77% in both arms), and
baseline bisphosphonate use was less frequent in the everolimus plus
exemestane arm versus placebo plus exemestane arm (44% and 54%,
respectively) [41]. Progressive disease in the bone occurred in 13% of
patients treated with everolimus plus exemestane compared with 19%
treated with placebo plus exemestane [41].
Median PFS in patients with bone-only metastasis treated with
everolimus plus exemestane and placebo plus exemestane was 12.9
and 5.3 months, respectively, indicating a 67% reduction in the risk
of progression (HR, 0.33; 95% CI, 0.21-0.53; P b .05); this was
similar to the risk reduction of 55% observed in the overall
population (HR, 0.45; 95% CI, 0.38-0.54; P b .0001) [28].
Bone marker levels, including bone-specific alkaline phosphatase
(BSAP), amino-terminal propeptide of type 1 collagen (P1NP), and
C-terminal cross-linking telopeptide of type 1 collagen (CTX),
increased at 6 and 12 weeks relative to baseline in the placebo plus
exemestane arm, while levels decreased in the everolimus plus
exemestane arm [41]. The differences between the everolimus plus
exemestane and the placebo plus exemestane arms were significant
from baseline to week 6 compared with the placebo arm [26% for
BSAP; 56% for P1NP; 36% for CTX (P b .001 for all)]. Similar
trends were observed at week 12 [20% (P = .005) for BSAP; 66%
(P b .001) for P1NP; 41% (P b .001) for CTX]. Reductions in bone
marker levels were observed irrespective of the presence of bone
metastases or baseline bisphosphonate use.
The results suggest that combination therapy with everolimus and
exemestane may help lower disease progression in the bone and may
suppress increased bone turnover and resorption observed with
exemestane monotherapy [41]. However, these observations are from
exploratory analyses and need to be confirmed in larger trials, and it is
currently unknown if the improvement in bone turnover is sustained
throughout the duration of everolimus therapy.
Asian Subset
As the effect of anticancer treatments may be influenced by
ethnicity, a post hoc analysis of the results from BOLERO-2 in Asian
versus non-Asian patients was completed [29]. In the study, 20% of
enrolled patients were Asian (143/724, with 74% being of Japanese
origin), with 69% of Asian patients receiving everolimus and 31%
placebo. Baseline patient and disease characteristics among Asian and
non-Asian patients were comparable, but Asian patients were younger
and had a better performance status than non-Asian patients. The
median duration of exposure to treatment was longer in the
Asian population.
Everolimus plus exemestane improved median PFS in Asian
patients by 38% (HR, 0.62; 95% CI, 0.41-0.94) and in non-Asian
patients by 59% (HR, 0.41; 95% CI, 0.33-0.50) [29]. Median PFS
duration among Asian patients was 8.5 compared with 4.1 months in
the everolimus plus exemestane and placebo plus exemestane arms,
respectively, and among non-Asian patients, it was 7.3 compared with
2.8 months.
AEs reported more commonly in Asian patients compared with
non-Asian patients receiving everolimus plus exemestane included
stomatitis (80% and 54%, respectively), rash (50% and 37%),
dysgeusia (31% and 20%), pneumonitis (23% and 15%), nail
disorder (22% and ~4%), increased lactate dehydrogenase (14% and4%), nasopharyngitis (22% and 7%), and interstitial lung disease
(13% and b1%) [29]. Pneumonitis, which was reported only in the
everolimus plus exemestane arm, was higher in Asian patients than in
non-Asian patients, while the frequency of grade 3/4 pneumonitis was
lower in Asian patients compared with non-Asian patients (2% vs
4%). The incidence of grade 3/4 AEs in the everolimus plus
exemestane arm was similar or lower in Asian patients compared with
non-Asian patients, apart from increased aspartate aminotransferase
(6% vs ~3%) and cough (3% vs b1%), and there were very few grade
4 AEs reported, regardless of treatment arm or ethnicity.
This analysis suggests that everolimus provides substantial clinical
benefit in both Asian and non-Asian patients, with similar safety
profiles [29].
Invasive Lobular Carcinoma
Invasive lobular carcinoma (ILC) is less common than infiltrating
ductal carcinoma (IDC) and has more favorable clinicopathologic
parameters compared with IDC tumors [42,43]. However, ILCs have
an increased propensity for multifocal and multicentric distribution,
bilaterality, and different patterns of metastatic involvement
compared with IDCs, and as a result, survival prognosis is generally
worse [42,43]. An exploratory analysis of the BOLERO-2 study
evaluated patients with ILC [30]. Upon local assessment, the median
PFS was 6.9 months in the everolimus plus exemestane arm versus
4.2 months in the placebo plus exemestane arm, respectively (HR =
0.59; 95% CI, 0.37-0.95) [30]. The AE profile between the two
treatment groups was similar to that of the overall study population.
Quality of Life
Although treatments for advanced breast cancer should maintain or
improve QoL [44], disease- and treatment-related factors may
adversely affect health-related QoL [45,46]. The health-related
QoL effect of everolimus was assessed as a secondary end point in
the BOLERO-2 study [44]. At a median follow-up of 18 months,
time to definitive deterioration (TDD), defined as a 5% change from
baseline European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire Core 30 health status score, was
higher with everolimus plus exemestane than with placebo plus
exemestane (8.3 vs 5.8 months; P = .0084) [44]. Although TDD
based on a 10-point minimally important difference, which is
reported to be a relevant change in other cancer populations, was
higher with the everolimus plus exemestane versus placebo plus
exemestane arms, the difference was not statistically significant (11.7
vs 8.4 months; P = .1017) [44]. Greater benefits were found in
patients with an ECOG performance status score of 1 or 2 and in
those aged b65 years.
To further assess the impact of everolimus therapy on disease
burden, additional post hoc analyses of health-related QoL outcomes
from the BOLERO-2 trial at a median follow-up of 18 months have
been reported [47]. In a sensitivity analysis assessing the effect of
study discontinuation on or before week 24 of treatment, patients
who discontinued early from the study had worse health-related QoL
decline on both treatments, while patients treated with everolimus
plus exemestane who did not discontinue early from the study had
stable QoL outcomes compared with those receiving placebo plus
exemestane.
Everolimus treatment did not affect QoL compared with placebo
in Asian patients, with a median TDD of 8.4 months (95 % CI,
6.9-11.1) in the everolimus plus exemestane arm compared with
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(HR, 0.79; 97.5% CI, 0.44-1.44) [29].
The improvement in TDD of global health status with everolimus
in combination with exemestane was shown despite a higher
incidence of grade 3/4 AEs and discontinuations because of AEs
with everolimus plus exemestane, and it is suggested that the clinical
benefit of everolimus plus exemestane therapy may have contributed
to this effect [44].
Exploratory Analysis of Biomarkers
A retrospective, exploratory analysis of the BOLERO-2 study
evaluated genetic variations of cancer-related genes using next-gen-
eration sequencing from formalin-fixed, paraffin-embedded archival
tissues collected during patient recruitment and explored the
correlations of these genetic alterations with everolimus benefit
[48]. Through the individual evaluation of alterations of the four
most commonly mutated genes in this analysis (PIK3CA, cyclin D1,
checkpoint gene p53, and fibroblast growth factor receptor 1) or their
respective pathways, the PFS benefit of everolimus in patients with
these altered pathways was similar to the PFS benefit seen in the
overall study population [48].
However, when the data were sorted by minimal or multiple
genetic alterations, patients with wild-type genes or only a single
genetic alteration in the PIK3CA, cyclin D1, or fibroblast growth factor
receptors 1 and 2 gene (76% of the patients in this exploratory
analysis) derived greater benefit from everolimus than the overall
population (HR, 0.27; 95% CI, 0.18-0.41) [48]. In all, these data
suggested a complex association between upstream and downstream
components of the mTOR pathway and may help generate new
hypotheses for combinations of novel targeted therapies after
prospective validation in independent patient cohorts.
Tolerability Considerations for Everolimus Use in
Breast Cancer
mTOR inhibitors are associated with a unique AE profile, which
includes stomatitis, infection, rash, noninfectious pneumonitis
(NIP), hyperglycemia, and hyperlipidemia, that is not commonly
observed with endocrine therapies [49]. Of note, hyperglycemia and
dyslipidemia are of special interest to postmenopausal women who
are already at increased risk for age-related metabolic abnormalities.
Most AEs with everolimus are not life threatening and are reversible
with supportive care and with interruption and/or adjustment of
everolimus dosing [50]. Available management strategies to
minimize the occurrence and severity of AEs associated with
everolimus have been described [49,51–53]; in patients with severe
AEs, temporary interruption or dose reduction of everolimus is
recommended, and discontinuation of therapy is recommended for
grade 4 events (Table 3) [22].Dose Intensity, Exposure, and Modifications
In BOLERO-2, the median duration of exposure to everolimus
was 23.9 weeks (range, 1.0-123.3) at a median follow-up of
18 months, and the median dose intensity was 8.6 mg/day [24,49].
In the everolimus plus exemestane arm, 46% of patients had a relative
everolimus dose intensity between 0.9 and b1.1, 19% of patients had
a relative dose intensity between 0.7 and b0.9, and 17% of patients
had a relative dose intensity between 0.5 and b0.70; this suggests that
doses of the intended therapies were near the recommended optimal
dose in the majority of patients [54].Dose interruptions/reductions were required in 62% of patients
treated with everolimus plus exemestane and in 12% treated with
placebo plus exemestane [49]. Among the 1065 instances of dose
interruptions/reductions with everolimus, there were 360 dose
reductions and 705 dose interruptions. The median time to first
dose reduction was 55 days (range, 6-483) in the overall population,
the median duration of dose reductions for everolimus was 29 days
(range, 1-672), and the median duration of dose interruption was
7 days (range, 1-41).
More patients in the everolimus plus exemestane arm required at
least one dose interruption or reduction for AEs (≥1 dose
interruption: 56% for everolimus, 15% for exemestane; ≥1 dose
reduction: 38% for everolimus, b1% for exemestane) than did
patients in the placebo plus exemestane arm (≥1 dose interruption:
10% for placebo, 5% for exemestane; ≥1 dose reduction: 3% for
placebo, 0 for exemestane), with the greatest number of dose
interruptions/reductions attributed to everolimus [49]. The most
common AEs leading to dose interruptions/reductions in the
everolimus plus exemestane arm were stomatitis (24%), pneumonitis
(8%), alanine aminotransferase increase (5%), aspartate aminotrans-
ferase increase (4%), dyspnea (4%), blood creatinine increase (3%),
and fatigue (3%) [49]. There was no predominant AE leading to dose
interruptions/reductions in the placebo plus exemestane arm.
Treatment discontinuations because of treatment-emergent AEs
were higher in the everolimus plus exemestane arm (26% for
everolimus; 9% for exemestane) than in the placebo plus exemestane
arm (5% for placebo; 3% for exemestane); pneumonitis (6%),
stomatitis (3%), dyspnea (2%), and fatigue (2%) were the most
common AEs leading to treatment discontinuation in the everolimus
plus exemestane arm [49]. Full-dose everolimus was resumed within
2 weeks in 76% and within 3 weeks in 88% of patients who had dose
interruptions/reductions, with a median time of 8 days (range, 2-333)
to resumption of full-dose everolimus in patients who were able to
resume study drug.
Among the 1065 instances of everolimus dose interruptions/
reductions (705 dose interruptions; 360 dose reductions), 44%
resolved with resumption of full dosing of everolimus at 10 mg/day
and 76% resolved within 2 weeks, with most patients who resumed
the full 10-mg everolimus dose doing so within 2 weeks [49]. A
limited number of patients who underwent dose reductions because
of AEs were able to reescalate everolimus to the 10 mg/day dose.
Stomatitis
Stomatitis associated with mTOR inhibitors occurs as aphthous-
like lesions that are discrete, relatively shallow, well demarcated with
surrounding erythematous margins [55–57], and most commonly
occurring in nonkeratinized mucosa [53,58].
In BOLERO-2, the frequency of stomatitis (i.e., stomatitis and
related events) was higher in the everolimus plus exemestane versus
placebo plus exemestane arm (67% vs 12%), with grade 3 events
occurring in 8% and b1% of patients, respectively; no grade 4 events
were reported for either arm [49]. Greater than one third of grade ≥2
stomatitis events occurred in the first 2 weeks of everolimus therapy. In
the 39 patients with grade ≥3 stomatitis, 97% had resolution to grade
≤1 following dose interruption/reduction after a median of 3.1 weeks
and 82% had complete resolution after a median of 7.4 weeks.
As outlined in Table 3, management of everolimus-associated
stomatitis includes dose interruptions/reductions, discontinuations,
and medical therapy depending on severity [22].
Table 3. Management Recommendations for Nonhematologic AEs as Based on the BOLERO-2 Study Protocol [22]
Severity Everolimus Dose Modification * Management Recommendations
Stomatitis
Grade 1 • No dose adjustment required • Manage with nonalcoholic or saltwater (0.9%) mouthwash several times a day
Grade 2 • Temporary dose interruption until recovery to grade ≤1, then reinitiate everolimus at a lower dose
• If recurrence at grade 2, interrupt dose until recovery to grade ≤1, and reinitiate everolimus at a lower dose
• Manage with topical analgesic mouth treatments with or without topical
corticosteroids
Grade 3 • Temporary dose interruption until recovery to grade ≤1, then reinitiate everolimus at a lower dose • Manage with topical analgesic mouth treatments with or without topical
corticosteroids
Grade 4 • Discontinue everolimus • Treat with appropriate medical therapy
NIP
Grade 1 • No dose adjustment required • Initiate appropriate monitoring
Grade 2 • Consider interruption of therapy and then reinitiate everolimus at a lower dose
• Discontinue treatment if failure to recover within 4 weeks
• Rule out infection
• Consider treatment with corticosteroids until symptoms improve to grade ≤1
Grade 3 • Interrupt everolimus until symptoms resolve to grade ≤1
• Consider reinitiating everolimus at a lower dose
• If toxicity recurs at grade 3, consider discontinuation
• Rule out infection
• Consider treatment with corticosteroids
Grade 4 • Discontinue therapy • Rule out infection
• Consider treatment with corticosteroids
Other nonhematologic toxicities (excluding metabolic events)
Grade 1 • No dose adjustment if toxicity tolerable • Initiate appropriate medical therapy and monitor
Grade 2 • No dose adjustment if toxicity tolerable
• If toxicity intolerable, temporary dose interruption until recovery to grade ≤1, then reinitiate everolimus at the same dose
• If toxicity recurs at grade 2, interrupt everolimus until recovery to grade ≤1, and then reinitiate everolimus at a lower dose
• Initiate appropriate medical therapy and monitor
Grade 3 • Temporary dose interruption until recovery to grade ≤1
• Consider reinitiating everolimus at a lower dose
• If toxicity recurs at grade 3, consider discontinuation
• Initiate appropriate medical therapy and monitor
Grade 4 • Discontinue • Treat with appropriate medical therapy
Metabolic events
Grade 1 • No dose adjustment required • Initiate appropriate medical therapy and monitor
Grade 2 • No dose adjustment required • Manage with appropriate medical therapy and monitor
Grade 3 • Temporary dose interruption
• Reinitiate everolimus at a lower dose
• Manage with appropriate medical therapy and monitor
Grade 4 • Discontinue everolimus • Treat with appropriate medical therapy
* If a dose reduction is required, the suggested dose is about 50% lower than the dose previously administered.
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NIP is a nonmalignant infiltration of the lungs associated with
mTOR inhibitors [51,52,59] and is observed in radiographic findings
as ground-glass opacity with or without focal consolidation
predominantly in the lower lobes of the lungs [50,51]. Patients
with NIP may be asymptomatic or have nonspecific respiratory
symptoms, including dyspnea, cough, hypoxia, and (rarely) pleural
effusion, thereby complicating diagnosis. Fever has also been
reported, requiring infection to be excluded as a cause.
As outlined in Table 3, management of everolimus-associated NIP
includes dose interruptions/reductions, discontinuations, and med-
ical therapy depending on severity [22]. Because symptoms are often
subtle and lung metastases may complicate diagnosis, it isrecommended that a thorough medical history be obtained and
alternative treatment for patients with chronic obstructive pulmonary
disease or significant pulmonary fibrosis be considered [51].
In BOLERO-2, 20% of patients in the everolimus plus exemestane
arm and b1% in the placebo plus exemestane arm experienced NIP,
with grade 3 events occurring in 4% of patients treated with
everolimus and one grade 4 event reported [49]. There were few early
NIP events and no plateau in occurrence. About 25% of grade ≥2
NIP events occurred within the first 12 weeks of everolimus therapy.
In patients with grade ≥3 NIP treated with everolimus plus
exemestane, 80% experienced resolution to grade ≤1 after a median
of 3.8 weeks and 75% experienced complete resolution after a median
of 5.4 weeks.
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mTOR inhibitor–induced rash typically occurs as maculopapular
or acneiform lesions, often with pruritus [60], with skin color and/or
nail color changes, dry skin, or eczema also reported [61]. The rash
typically occurs on the trunk, scalp, face, and neck, with the
extremities also commonly affected [60].
In BOLERO-2, the incidence of rash was 39% in patients treated
with everolimus plus exemestane and 7% in patients treated with
placebo plus exemestane [24]. Grade 3 rash occurred in 1% of
patients treated with everolimus, and no patients experienced grade 4
rash [24]. Rash led to discontinuation of study treatment in 2% and
0% of patients in the everolimus plus exemestane and placebo plus
exemestane arms, respectively [49].
As outlined in Table 3, management of everolimus-associated rash
includes dose interruptions/reductions, discontinuations, and med-
ical therapy depending on severity [22].
Hyperglycemia
mTOR is involved in glucose homeostasis, and mTOR inhibitors
have an impact on glycemic control [62]. In BOLERO-2, fasting
serum glucose was monitored before the start of everolimus therapy
and periodically thereafter, with optimal glycemic control achieved
before starting study therapy [49]. Hyperglycemia was managed with
appropriate medical therapy and monitoring [22]. For grade ≥2
hyperglycemia events requiring dose modifications of study drug,
biochemistry tests were repeated until recovery to the baseline value
or to grade 1 [49]. These recommendations from BOLERO-2 are
consistent with those from a task force of the National Cancer
Institute Investigational Drug Steering Committee assessing hyper-
glycemia and hyperlipidemia with PI3K/Akt/mTOR inhibitors [63].
In BOLERO-2, a notable number of patients in both treatment
arms had diabetes mellitus or impaired glucose tolerance at baseline
(9% in the everolimus plus exemestane arm and 10% in the placebo
plus exemestane arm); 16% of patients treated with everolimus
experienced hyperglycemia or new-onset diabetes mellitus compared
with 3% in the placebo arm [49]. Grade 3/4 events occurred in 6%
and 1% of patients, respectively, and approximately 50% of the grade
≥2 events occurred in the first 6 weeks of everolimus therapy. Among
patients with grade ≥3 events in the everolimus plus exemestane arm,
46% experienced resolution to grade ≤1 after a median of 29.1 weeks.
Hyperlipidemia
Because fat metabolism is regulated by the mTOR signaling
pathway, mTOR inhibition may contribute to hyperlipidemia [62].
In BOLERO-2, hyperlipidemia and hypertriglyceridemia were
treated according to local best clinical practice, and pretreatment
status and dietary habits were considered during management [49].
Hyperlipidemia was monitored through fasting blood samples, and
patients were monitored clinically and through serum biochemistry
for the development of rhabdomyolysis and other AEs as required in
the product labels for 3-hydroxy 3-methylglutaryl coenzyme A
reductase inhibitors [49].
In BOLERO-2, there was a higher incidence of hyperlipidemia in
patients treated with everolimus plus exemestane versus those treated
with placebo plus exemestane (14% and 2%, respectively), with an
incidence of grade 3/4 events of 1% and 0%, respectively [49]. A
quarter of the patients treated with everolimus who experienced grade
≥3 hyperlipidemia had resolution of the event to grade ≤1, with a
median time to resolution not assessable because of low event rates.Hematological Considerations
Bone marrow suppression is a common toxicity observed with
mTOR inhibitor therapy [50]. In phase II/III trials of everolimus in
breast cancer, anemia was reported in 11% to 69%, thrombocyto-
penia in 12% to 60%, and neutropenia in 10% to 66% of patients
receiving everolimus [50]. In BOLERO-2, the most common
hematologic toxicities were decreases in hemoglobin (68% in the
everolimus plus exemestane arm vs 40% in the placebo plus
exemestane arm), white blood cells (58% vs 28%), platelets (54%
vs 5%), lymphocytes (54% vs 37%), and neutrophils (31% vs
11%) [22]. Grade 3/4 hematologic events included decreased
hemoglobin (7% in the everolimus plus exemestane arm vs 1% in
the placebo plus exemestane arm), white blood cells (1% vs 6%),
platelets (3% vs b1%), lymphocytes (12% vs 6%), and neutrophils
(2% vs 2%), with grade 4 hematologic events occurring in both
treatment arms (1% vs 3%).
Most hematologic events with everolimus were grade 1/2, which
does not necessitate interruption of therapy [50]. For grade 3 events,
interruption of everolimus therapy and resumption at a lower dose is
recommended. For grade 4 events, discontinuation of everolimus
therapy is recommended.Infections
Everolimus has immunosuppressive effects that may predispose
patients to bacterial, viral, or protozoal infections, including
opportunistic infection or reactivation of prior infection [22,51].
Bacterial infections, invasive fungal infections, and hepatitis B virus
reactivation in previously infected patients have been reported with
everolimus treatment in various malignancies.
In BOLERO-2, 6.6% of patients treated with everolimus plus
exemestane experienced grade 3/4 infection, with 84% of these
patients having resolution of the infectious event to grade ≤1, with a
median time to resolution of 3 weeks [49].Conclusions and Future Directions
The BOLERO-2 trial demonstrated a clinically meaningful improve-
ment in PFS with everolimus plus exemestane therapy in patients
with hormone receptor–positive/HER2− advanced breast cancer
[24,64], and the consistency of the results were demonstrated across
all assessed subgroups [24]. This efficacy benefit with everolimus
comes with an increased incidence of mTOR inhibitor–associated
toxicities. However, the TDD of performance status and QoL were
not statistically different between treatment groups [44]. In general,
class-effect AEs apart from NIP had a relatively short time to onset,
with incidence tapering off thereafter. Grade 3/4 AEs occurred at a
low rate and most resolved to grade ≤1 fairly quickly, suggesting that
management recommendations for everolimus-related AEs, which
include dose interruptions/reductions, enable continued treatment in
most cases [49].
The identification and management of mTOR-associated AEs are
critical aspects of patient treatment and should be approached
proactively through dose interruptions and reductions, with return to
active treatment on resolution. This approach appears to adequately
manage cases of stomatitis and rash, but more extensive measures for
the management of NIP may be required. Education of both
physicians and patients on the unique AE profile of everolimus is
recommended. Baseline screening for suspected lung disease,
hypercholesterolemia, or diabetes and optimization of the
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in decreasing the severity and frequency of AEs [50].
Although BOLERO-2 has provided clinically relevant results for
everolimus in combination with exemestane, an important consid-
eration might be the selection of the most appropriate patients for
everolimus therapy [65]. Considering the results of BOLERO-2,
everolimus plus exemestane may be appropriate as a standard option
in treating postmenopausal patients with hormone receptor–positive/
HER2− advanced breast cancer with prior exposure to nonsteroidal
aromatase inhibitors who are medically fit, who would be followed
closely by their oncologist, and who are aware of the toxicity profile
and associated management strategies for everolimus [64]. Consid-
eration of use of everolimus only in prior hormone-sensitive breast
cancer that has developed acquired resistance to nonsteroidal
aromatase inhibitors has been suggested [65], and further evidence
in the first-line setting should be obtained. Importantly, the
subanalyses of BOLERO-2 showed that the benefit of everolimus
therapy was similar in patients with no prior therapy for advanced
disease and in those with more heavily treated cancer. As such, there is
currently no strong evidence that resistance to prior therapy is a requisite
for the efficacy of everolimus, or that everolimus in combination with
exemestane should only be considered for second- or third-line therapy
of hormone receptor–positive/HER2− advanced breast cancer. Further
research is needed in hormone receptor–positive/HER2− patient
populations to further evaluate the appropriate patients that could be
treated with everolimus.
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